Document Detail


Advantages of Novel BioMimeTM Sirolimus Eluting Coronary Stent System. Moving towards biomimicry.
MedLine Citation:
PMID:  22322571     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Since the first reported use of percutaneous transluminal coronary angioplasty (PTCA), advancements in interventional cardiology arena have been fast paced. Within the last ten years, these developments have been exponential. Developers & clinicians are fast adapting from the learning curve awarded by the time course of DES evolution. In that light BioMimeTM Sirolimus Eluting Coronary Stent comes as a fresh thought in taking stents towards a biomimicry concept. The stent is built on an ultra-low strut thickness (65 µm) cobalt chromium stent platform, using an intelligent hybrid of close and open cells allowing for morphology mediated expansion, employs a well known anti-proliferative - Sirolimus that elutes from a biodegradable co-polymer formulation in 30days and ensures high coating integrity and low coating thickness of 2 µm. The resultant stent demonstrates almost 100% endothelialization at 30days in preclinical model and zero percent MACE >18 months in the primary efficacy and safety clinical study.
Authors:
K Upendra; B Sanjeev
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  60     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  23-31     Citation Subset:  IM    
Affiliation:
Executive Director and Dean, Fortis Escorts Heart Institute and Research Centre, New Delhi, India2 Meril Life Sciences Pvt. Ltd., Vapi, India - kaul.upendra@gmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ex vivo and preclinical assessment of an endothelial progenitor cell capturing bioengineered stent.
Next Document:  Advantages of MGuard coronary stent system.